We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
10.00 | 0.56% | 1,790.50 | 1,790.00 | 1,790.50 | 1,794.00 | 1,780.00 | 1,784.00 | 602,727 | 11:04:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.98 | 73.84B |
Date | Subject | Author | Discuss |
---|---|---|---|
19/7/2021 09:47 | The whole FTSE is broken and has been for some time. spud | spud | |
19/7/2021 09:30 | Once again, pathetic market response to GSK news ..... :0( | tradermichael | |
19/7/2021 09:23 | I guess we all loaded up early this morning | netcurtains | |
18/7/2021 23:42 | Excellent news at last. Next to come a combined annual covid/flu jab that also uses the adjuvant technology platform. Lots in the kit bag yet. | eurofox | |
18/7/2021 15:47 | I posted some time ago that I felt the market for a Covid treatment could be very large. So we have GSK and Roche up there; there will be others. I would assume that Covid is here to stay for sometime so drugs that can manage the illness are as important as the vaccines. | alphorn | |
18/7/2021 14:43 | Blimey, some good news for a change! spud | spud | |
18/7/2021 13:00 | Let us see now @ pound a piece that will give us 3000 quids to add to the dividend fund . | abdullla | |
18/7/2021 13:00 | Interesting developments, and here in the uae:https://www.then | dartboard1 | |
18/7/2021 10:40 | Switzerland has reserved 3,000 doses of the GlaxoSmithKline monoclonal sotrovimab drug to treat patients infected with Covid-19. This adds to the 3,000 doses of a similar medicine, RegN-Cov 2, developed by Switzerland’s Roche and US biotech company Regeneron. Monoclonal antibodies, which are cloned in culture and injected into patients, are seen as highly promising treatments to neutralise the virus, particularly in serious cases of infection. The antibody was discovered by Swiss company Humabs BioMed. Although the sotrovimab drug has yet to be granted regulatory approval in Switzerland, trials by GlaxoSmithKline show promising results. | alphorn | |
17/7/2021 08:12 | BBC News - UK plans biggest flu vaccine rollout this winterhttps://www.bb | coxsmn | |
16/7/2021 17:47 | I Like steak and kidney pie and chips Friday nights is Chippy night | notbitcoin | |
16/7/2021 16:24 | Looks good - Kidney drug trials are hot news at present. | netcurtains | |
16/7/2021 16:02 | GlaxoSmithKline's Anemia Drug Met Primary Endpoint in Five Phase 3 Studies 16/07/2021 12:50pm Dow Jones News Friday 16 July 2021 GlaxoSmithKline PLC said Friday that five Phase 3 studies of a drug used to treat patients with anemia due to chronic kidney disease have met their primary efficacy endpoint. The British pharmaceutical major said the studies evaluated the efficacy and safety of the drug, named daprodustat, as part of a Phase 3 program named Ascend. As a primary endpoint, the drug demonstrated an improvement in hemoglobin levels both in patients who weren't receiving other treatments and in patients treated with another standard treatment option, the company said. GSK said daprodustat is currently only approved in Japan for patients with renal anemia and that it isn't approved in any other country. spud | spud | |
16/7/2021 12:14 | Some good news for CKD sufferers ... no idea if it's good news for the share price I don't think EW has communicated well with the City or moved fast enough. Elliot criticism in this regard was spot on. The strategy outlined seems fairly sensible, although I wonder if more value could be released by splitting in 3, vaccines, pharma and consumer. I don't think the consumer business will survive long as a stand alone, and will have many suitors. | alex1621 | |
16/7/2021 12:13 | lovewinshatelosses: Well said. But this is a message board not a textbook. If I want to make the case for abolishing toff schools I would probably need about 1000 pages. As many of you might know I'm pretty much in favour of abolishing all bricks and mortar schools - I'm a home school fan for - See my first post of WEY Education - (a clue it was years before the last thread was created). Earliest I can find is Feb 2017 - Well before Covid: | netcurtains | |
16/7/2021 12:04 | I am sorry netcurtains, but I am going to have to highlight that EW did not pull herself up from a sink estate in 'da ends'. A background as posh as they come and could not be more public school as far as I can see, which some basic internet searches will outline. Which is absolutely fine as far as I am concerned, but your post has a dig at the public school culture in the UK...but seems to overlook this fairly significant fact :) Anyway, the only way to silence the doubters is to deliver company performance that leads to a share price well north of here. We are not talking about someone who is new to the job either. I want to see this happen and do not care who is in charge to achieve this end. | lovewinshatelosses | |
16/7/2021 11:43 | Ecoglaxo would be better. Or even better still, just Glaxo, but being led by an experienced pharma professional and not one with a career in lipstick. | pierre oreilly | |
16/7/2021 10:28 | They should put an i in front of its name or and X at the end. The market goes crazy for that sort of stuffi-glaxoGlaxo-xA | beergut | |
16/7/2021 09:14 | Undervalued atm, Biotech is the future, wondering who the developer will be ( Tommy Clarkes?) fill your boots gla | charlie9038 | |
16/7/2021 08:58 | What I dont understand is GSK has double the NAV of AZN and miles bigger profits and turnover. But the market does not like it. What does GSK need to do to be liked? It has the profits, it has the turnover, it has the exciting possibilities thrown up by the demerger. I just dont understand why the city is so thick? I suspect its all these public school Rodneys who dont like girls. I suspect if every public school in the UK was closed down we'd be a far more successful and dynamic country. A bit like Scandinavia or Germany or one of the other non-public school powerhouses. GSK is a great company dont let the Rodneys tell you otherwise. | netcurtains | |
16/7/2021 08:25 | I suspect new strong management would transform the Company. However, EW still has support.Baffling.... | spud | |
16/7/2021 08:11 | I remember when they reached £20 in 1996. The company has had terrible leadership over the years. The culture is all wrong. | chillpill | |
16/7/2021 08:04 | Its opened really low. Blimy. | netcurtains | |
16/7/2021 07:58 | Big project, good for the UK. GLA | charlie9038 | |
16/7/2021 06:27 | GlaxoSmithKline seeks developer to create giant biotech research centrehttps://www.th | ayl30 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions